Dr. Handelin was Director of the DNA Diagnostics Laboratory at Integrated Genetics (now Genzyme Genetics) starting in 1987 where she helped establish what became the largest commercial DNA testing laboratory in the world. Under her direction, the DNA Diagnostics laboratory was a technological and clinical practice leader in genetic diagnostics, setting the standard for low cost, high fidelity analysis of many mutations in genetically complex diseases and the first laboratory to offer commercial carrier and prenatal gene testing for Huntington's Disease (1987), Cystic Fibrosis (1990), Spinal Muscular Atrophy (1992), Tay Sachs Disease (1993 large scale carrier screening) and Fragile X (1994).

Since 1995, Dr. Handelin has provided business and technical consulting guidance for industry leaders in genetic diagnostics, pharmacogenetics, and drug development. Dr. Handelin has also served on a variety of federal committees and advisory panels on genetic testing and pharmacogenetics, including the Health and Human Services Secretary's Advisory Panel on Genetics, Health and Society and was the Principal Investigator on a DOE ELSI grant on "The Responsibility of Oversight in Genetics Research: How to Enable Effective Human Subjects Review of Public and Privately Funded Research Programs." Dr. Handelin earned her Ph.D. at the Oregon Health Sciences University and the Massachusetts Institute of Technology.

"Dr. Handelin brings to DNAPrint extensive research and development expertise in the field of Diagnostics, which is crucial to DNAPrint Pharmaceuticals' future growth and development. We are very pleased to be working with her on the development of our diagnostic projects," said Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc.

"DNAPrint Pharmaceuticals is particularly fortunate to have Dr. Handelin lead our diagnostics division. She possesses the technical expertise and business savvy to develop and bring to market products which address significant market opportunities in an efficient and well executed manner," commented Richard Gabriel, President and CEO of DNAPrint.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.